

## कार्यालय महानिदेशक लेखापरीक्षा (केन्द्रीय व्यय)

Office of the Director General of Audit (Central Expenditure) डी जी ए सी आर भवन, इन्द्रप्रस्थ एस्टेट, नई दिल्ली-110 002 DGACR Building, Indraprastha Estate, New Delhi-110 002

No. CAW/1-27/KAPL/2023-24/ 130-131

Date: 31.08.2023

सेवा में.

प्रबंध निदेशक, कर्नाटक एंटीबायोटिक्स और फार्मास्युटिकल्स लिमिटेड, अर्का-व्यापार केंद्र, प्लॉट न 37, साइट न. 34/4, एन.टी.टी.एफ. मेन रोड, पीन्या औद्योगिक क्षेत्र, दूसरा चरण, वैंगलोर-560058

विषय: भारत के नियंत्रक एवं महालेखापरीक्षक द्वारा कम्पनी अधिनियम 2013 के अनुच्छेद 143 (6)(b) के अंतर्गत कर्नाटक एंटीबायोटिक्स और फार्मास्युटिकस्स लिमिटेड के 31 मार्च 2023 को समाप्त वर्ष के वित्तीय खातों पर टिप्पणियां।

महोदय,

इस पत्र के साथ कम्पनी अधिनियम 2013 की धारा 143(6) (बी) के तहत कर्नाटक एंटीबायोटिक्स और फार्मास्युटिकल्स लिमिटेड के 31 मार्च 2023 को समाप्त वर्ष के वित्तीय खातों पर "Non Review Certificate" भेजा जा रहा है।

इस पत्र की पावती भेजने की कृपा करें।

भवदीय,

संलग्नः यथोपरि

निदेशक (CAW)

Ph.: 91-11-23702422 Fax: 91-11-23702271 E-mail : dgace@cag.gov.in Website : https://cag.gov.in/cen/new-delhi-iii/ten COMMENTS OF THE COMPTROLLER AND AUDITOR GENERAL OF INDIA UNDER SECTION 143(6) (b) OF THE COMPANIES ACT, 2013 ON THE FINANCIAL STATEMENTS OF KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LIMITED FOR THE YEAR ENDED 31 MARCH 2023

The preparation of financial statements of Karnataka Antibiotics & Pharmaceuticals Limited for the year ended 31 March 2023 in accordance with the financial reporting framework prescribed under the Companies Act, 2013 (Act) is the responsibility of the management of the company. The statutory auditor appointed by the Comptroller and Auditor General of India under section 139 (5) of the Act is responsible for expressing opinion on the financial statements under section 143 of the Act based on independent audit in accordance with the standards on auditing prescribed under section 143(10) of the Act. This is stated to have been done by them vide their Audit Report dated 18.07.2023.

I, on behalf of the Comptroller and Auditor General of India, have decided not to conduct the supplementary audit of the financial statements of **Karnataka Antibiotics & Pharmaceuticals Limited** for the year ended 31 March 2023 under section 143(6)(a) of the Act.

For and on behalf of the Comptroller & Auditor General of India

Place: New Delhi

Dated: 31.08.2023

(Rajiv Kumar Pandey)

Director General of Audit (Central Expenditure)